Market capitalization | $15.89m |
Enterprise Value | $27.69m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 7.91 |
P/S ratio (TTM) P/S ratio | 4.54 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 22.27% |
Revenue (TTM) Revenue | $3.50m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast HCW Biologics Inc:
1 Analyst has issued a forecast HCW Biologics Inc:
Sep '24 |
+/-
%
|
||
Revenue | 3.50 3.50 |
22%
22%
|
|
Gross Profit | 0.36 0.36 |
186%
186%
|
|
EBITDA | -24 -24 |
21%
21%
|
EBIT (Operating Income) EBIT | -24 -24 |
19%
19%
|
Net Profit | -37 -37 |
89%
89%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
HCW Biologics, Inc. operates as a holding company which engages in the research and development of immunotherapies. It focuses on cancer and aging-associated diseases. The company was founded by Hing C. Wong on April 2, 2018 and is headquartered in Miramar, FL.
Head office | United States |
CEO | Hing Wong |
Employees | 45 |
Founded | 2018 |
Website | www.hcwbiologics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.